Tuberculosis Kit

About ICHORtec

ICHORtec is a private, early-stage biotech company pioneering a novel molecular interaction analysis platform. Its core innovation, Quantum-FMB®, directly measures thermodynamic energy changes (ΔG) via fluorescence photon analysis to quantify binding affinity and specificity with high accuracy. The company is leveraging this platform to develop point-of-care diagnostic kits (e.g., for MRSA, Tuberculosis) and provide contract research services, such as CRISPR gRNA nomination, aiming to improve precision in diagnostics and therapeutic development. ICHORtec appears to be in a pre-revenue or early-revenue stage, focusing on validating its technology and building its product portfolio.

Therapeutic Areas

Other Tuberculosis diagnosis Drugs